Abstract
RESULTS
The median follow-up was 102.7 mo (range, 6-153.6).
The χ 2 and Fisher's exact tests showed that VEGFR1 expression was related to lymph node metastasis (P = 0.013), while no relationships between TUBB3 and clinicopathological features were observed. Univariate analysis showed that T stage, lymph node metastasis, tumor differentiation, VEGFR1 and TUBB3 mRNA expression were correlated to overall survival (OS) (P = 0.048, P = 0.003, P = 0.052, P = 0.003 and P = 0.015, respectively). Also, lymph node metastasis and VEGFR1 expression independently influenced OS by multivariate analysis (P = 0.027 and P = 0.033). VEGFR1 expression was positively correlated with TUBB3 (P = 0.024). The patients with low expression of both TUBB3 and VEGFR1 presented a better OS (P = 0.003). In addition, the receiver operating characteristic analysis suggested that the combination of lymph node metastasis and VEGFR1 had a more favorable prognostic value (P < 0.001).
CONCLUSION
VEGFR1 expression and lymph node metastasis independently and jointly affect survival. Moreover, low expression of VEGFR1 and TUBB3 presented a better OS in patients with non-metastatic rectal cancer, which might serve as a potential prognostic factor.
INTRODUCTION
Rectal cancer is one of the most diagnosed malignan cies among both males and females worldwide with worse outcomes than colon cancer [1, 2] . Clinically, patients showed various outcomes to multimodality therapies. Nowadays, personalized and precision medicine has become essential in the treatment of rectal cancer. Recent studies conducted gene expression profiling to predict the response and longterm prognosis of mali gnancies [3, 4] ; however, no consensus was achieved on prognostic gene profiling for rectal cancer.
Vascular endothelial growth factor (VEGF) posses ses a significant role in angiogenesis by binding to VEGFR1 and VEGFR2, which is required for cancer pro gression and metastasis [5, 6] . A phase Ⅱ trial indicated that VEGF could predict the pathological response to locally advanced rectal cancer patients treated with ne oadjuvant cetuximabbased chemoradiation [7] . In ad dition, class Ⅲ βtubulin (TUBB3) has been reported to play a critical role in tumor development and malignant transformation as a βtubulin isotype. The variable levels of expression of the gene have been reported in colon, lung, ovary, kidney, prostate, and throat cancer with solid tumors [810] . However, only a few studies focused on its role in rectal cancer.
Herein, our study attempted to explore the potential prognostic value of VEGFR1 and TUBB3 for longterm survival in nonmetastatic rectal cancer.
MATERIALS AND METHODS

Patients
Eighty cases of wellpreserved formalinfixed and pa raffin embedded tumor tissue specimens that had un dergone total mesorectal excision (TME) at the Fujian Cancer Hospital from March 2004 to November 2008 were retrospectively examined. Among these, two pa tients with previous malignancy and three with distant metastasis were excluded. Finally, 75 patients who ful filled the following inclusion criteria were enrolled in the study: (1) Pathologically confirmed as primary rectal adenocarcinoma; (2) underwent TME; (3) no evidence of distant metastasis; (4) no previous or concurrent ma lignancy; and (5) complete followup information was obtained.
The variables such as gender, age, preoperative carcinoembryonic antigen (preCEA), preoperative hemoglobin (preHb), distance to the verge, T stage, lymph node metastasis, venous invasion, and tumor differentiation were considered. The T stage and lymph node metastasis were rediagnosed based on the 8 th Edition of the American Joint Committee on Cancer (AJCC) [11] .
Treatments and follow-up
All patients underwent TME, including abdominoperine al resection and low anterior resection. Of these, eight cases received neoadjuvant chemoradiotherapy follow ed by TME. A total of 66 cases received 5fluorouracil (5FU)based chemotherapy. The overall survival (OS) was defined as the duration from the date of diagnosis to the last followup or the date of death due to any cause, which was obtained from the medical records and telephonic interviews.
Multiplex branched DNA liquidchip technology
The formalinfixed and paraffin embedded (FFPE) tu mor tissue specimens containing more than 70% of tumor cells were selected. The Multiplex branched DNA liquidchip (MBL) technology (Guangzhou SurExam Bio Tech Co., Ltd., China) was implemented to determine the mRNA expression levels of VEGFR1 and TUBB3. The FFPE tissue samples were lysed in the presence of proteinase K, at 56℃ for 2 h. Then, the lysate was transferred to a 96well plate containing the blocking reagent, capture beads with probes for VEGFR1 and TUBB3, and target genespecific probe sets. The san dwich nucleic acid hybridization was carried out for 16 h. The unbound RNA was removed by three washes with buffer under a vacuum system. The signal bound to the target mRNA was amplified with a streptavidin conjugated phycoerythrin solution at 50℃ for 30 min.
The fluorescence values of the samples were identifi ed and analyzed using Luminex 200 system (Luminex, Austin, TX, United States), which were regarded as the RNA expression levels of each gene. The cutoff point of mRNA expression affecting the survival was determined by the Cutoff Finder application [12] .
Statistical analysis
The end point of our analysis was OS. The association of gene expression level and clinicopathological featu res was studied by the χ 2 and Fisher's exact tests. The association between the mRNA expressions of VEGFR1 and TUBB3 was studied by the Spearman correlation test. The Kaplan-Meier test was used to analyze the OS, and Cox regression model (LR forward) was employed for univariate and multivariate analysis. Receiver operating characteristic (ROC) analysis was employed for assess ing the specificity as well as the sensitivity of predicting OS by specific parameters. The statistical significance of area under the ROC (area under curve, AUC) was calcu lated by Delong's test [13] . Pvalues < 0.05 were deemed significant. The statistical analysis was conducted by SPSS version 22.0 (IBM Corporation, Armonk, NY, United States). The statistical methods of our study were revie wed by Qianyu Ni from The First Affiliated Hospital of Fujian Medical University.
RESULTS
Patient characteristics
A total of 75 patients were enrolled in the present stu dy. The characteristics of nonmetastatic patients are summarized in Table 1 . Median followup time was 102.7 mo (range: 6.0153.6). The cohort comprised of 39 (52%) male and 36 (48%) female cases with the median age 52 years (range, 2974). Among these pati ents, 21 (36.8%) cases presented preCEA records that were higher than 5 ng/mL, while they could not be accessed for 18 cases. In the case of preHb, 26 (34.7%) patients were ≤ 120 g/L and the remaining were > 120 g/L. In terms of the tumor location, 46 (61.3%) patients had low rectal cancer (05 cm distance to verge), while the other 29 (38.7%) patients were > 5 cm. In all, 22 (29.3%) with lymph node metastasis positive and 53 (70.6%) were negative. Twenty (26.7%) patients were identified as poorly differentiated and 55 (73.3%) as moderatetowell differentiated. According to the Cutoff Finder software, 0.0575 and 0.2025 were considered as the optimal cutoff point for the VEGFR1 and TUBB3 expression value, respectively ( Figure 1 ). In addition, 36 (48%) and 22 (29.3%) patients showed a high expression of VEGFR1 and TUBB3, respectively.
Associations between mRNA expression and clinicopathological features
The correlations between VEGFR1/TUBB3 mRNA expre 353 WJGO|www.wjgnet.com Figure 3C ). Meanwhile, Kaplan Meier analysis showed that the rates of 1, 3, and 5year OS in positive lymph node metastasis patients with high expression of VEGFR1 vs others were 90.0% vs 98.2%, 35.0% vs 78.2%, and 30.0% vs 70.9%, respectively (P < 0.001) ( Figure 3D ). Finally, we combined the two independent prognos tic factors, lymph node metastasis and VEGFR1 expre ssion, to construct a prognostic model and supplement ed the VEGFR1 expression to the lymph node metastasis ssion and clinicopathological features were analyzed (Table 2) . A majority of the patients displayed positive lymph node metastasis in the highexpression group of VEGFR1 (P = 0.013). However, no significant difference was found between the expression level of TUBB3 ex pression and clinicopathological features (gender, age, preCEA, preHb, distance to the verge, T stage, lymph node metastasis and venous invasion, all P > 0.05).
Impact of VEGFR1 and TUBB3 on OS
The Cox regression analysis of OS influencing factors was shown in Table 3 . Univariate analysis showed that T stage, lymph node metastasis, tumor differentiation, and VEGFR1 and TUBB3 expression were significantly related to OS (P = 0.048, P = 0.003, P = 0.052, P = 0.003 and P = 0.015, respectively) (Figures 2, 3 A and  B) . Moreover, KaplanMeier analysis showed that the rates of 1, 3, and 5year OS in the TUBB3 low and highexpression groups were 94.9% vs 94.4%, 76.9% vs 52.8%, and 71.8% vs 47.2%, respectively (P = 0.017). The rates of OS in the VEGFR1 low and high expression groups were 98.1% vs 86.4%, 77.4% vs 36.4%, and 69.8% vs 36.4%, respectively (P = 0.003).
WJGO|www.wjgnet.com by ROC analysis to assess the improvement of the mo del for OS. The lymph node metastasis (AUC: 0.688, 95%CI: 0.567-0.808, P = 0.005) showed a better pro gnostic value than VEGFR1 expression (AUC: 0.635, 95%CI: 0.507-0.764, P = 0.045). Furthermore, a better prognostic value was shown when combining the lymph node metastasis and VEGFR1 expression (AUC: 0.748, 95%CI: 0.637-0.859, P < 0.001) (Figure 4 ).
DISCUSSION
Firstly, we evaluated the longterm prognostic value of VEGFR1 and TUBB3 expression after the diagnosis of nonmetastatic rectal cancer with a median follow up of 102 mo. Here, we found that VEGFR1 and TUBB3 expression affected OS in nonmetastatic rectal cancer by univariate analysis. Moreover, a favorable OS in both low expression of VEGFR1 and TUBB3 was noted as com pared to others. In addition, the association between VEGFR1 expression and lymph node metastasis was also assessed. The combination of lymph node metastasis and VEGFR1 expression might also provide a promising tool for the prognosis of nonmetastatic rectal cancer.
Reportedly, VEGFR correlates with poor prognosis, metastasis, and recurrence in various tumor types, in cluding breast and lung cancers [14, 15] . Moreover, previous studies demonstrated that VEGF plays a crucial role as a potent angiogenic factor in both experimental and hu man studies with respect to colorectal cancer progressi on and metastasis [1618] . The coexpression of VEGF and VEGFR1/2 in the nucleus stimulates the proliferation and migration of endothelial cells, thereby providing nutrition for growing tumors and establishing a continuity between tumor cells and host vasculature [19] . VEGFR1 is primarily localized in the nucleus of en dothelial cells; As the predominant receptor of the tu mor microenvironment, it is essential for the survival of endothelial cells [20] . Tsai et al [21] reported that the over expression of VEGF is a significant positive predictor for early postoperative relapse in stage ⅠⅢ colorectal cancer patients, leading to poor OS (P = 0.002). Similarly, Nriagu et al [22] reported that the overexpression of VEGF mRNA was an independent factor affecting OS as assessed by multivariate analysis (HR = 1.94, P = 0.005). Herein, we found that the low expression of VEGFR1 mi ght positively affect OS with a 5year OS of 69.8% for low
WJGO|www.wjgnet.com [23] , which might lead to poor survival in cancer patients.
A previous study evaluated VEGF expression in 117 colorectal adenocarcinoma patients, and confirmed WJGO|www.wjgnet.com current study showed that the low expression of TUBB3 had better OS in nonmetastatic rectal cancer patients as assessed by univariate analysis (5year OS, 71.8% vs 47.2%), although no significant difference was observed by multivariate analysis. Furthermore, Makarchenko et al [31] and Widow et al [32] reported that VEGFR1 regulated the chemoresistant genes such as TUBB3, which might result in the poor prognosis of lung and gastroesophageal cancers. The current study established a positive correlation bet ween VEGFR1 and TUBB3 (r = 0.315, P = 0.006), and a favorable OS was observed in both low expression groups (P = 0.003). Paradiso et al [33] had investigated the combination of TUBB3 and VEGFR1 in advanced breast cancer. Hypoxia in the tumor microenvironment promotes angiogenesis, and VEGFR1 is known to be related to angiogenesis [23] . TUBB3 was found to be involved in an adaptive response to low oxygen levels and poor nutrient supply in solid tumors [34, 35] . Therefore, we speculate that the underlying mechanism of the two correlations might be related to anoxic environments.
Notably, this study was limited to a smallsample retrospective analysis. Thus, additional mRNA expression data might help to establish a superior predictor. Finally, prospective data and large sample size are essential for further substantiation of the results.
We confirmed that the increased expression of VE GFR1 and TUBB3 might be negatively correlated with longterm prognosis of nonmetastatic rectal cancer.
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0.031) [24] . Similarly, our study implied that VEGFR1 ex pression was related to lymph node metastases (P = 0.013). However, whether the function of VEGF/VEGFR1 affects lymph node metastasis is yet unclear. Nagy et al [25] hypothesized that tumor cells in the circulation directly reached the regional lymph nodes through the supply vessels or blood vessellymph vessel junctions.
A retrospective study reported that VEGF expression could identify an unfavorable subgroup of patients with stage Ⅱ colon cancer for optimal treatment strategy (the recurrence rate was 50% for VEGFpositive vs 11.7% for VEGFnegative, P = 0.001) [26] . As shown by ROC curves in our analysis, though low sensitivity of VEGFR1 (44.1%), the specificity was high with 82.9%, which exerted a similar effect on prognosis as lymph node metastasis. Moreover, the sensitivity increased when combined wi th lymph node status, and a superior prognostic value was noted for the combination. Further identification of a group of lymph node metastasispositive with high VEGFR1 expression allows for selective treatment with adjuvant chemotherapy using antiangiogenic therapy, including VEGFR1 antisense and monoclonal antibodies, as well as postoperative followup.
Several clinical studies demonstrated that the incre ased expression of TUBB3 in various human malignan cies was related to low response rate and poor survival in patients treated with taxanebased chemotherapies [2730] . However, studies focusing on the relationship between TUBB3 and nonmetastatic rectal cancer are limited. The WJGO|www.wjgnet.com them showed a favorable prognostic value.
Research conclusions
We confirmed that the increased expression of VEGFR1 and TUBB3 might be negatively correlated with long-term prognosis of non-metastatic rectal cancer. Furthermore, VEGFR1 expression and lymph node metastasis affected the survival independently, as well as synergistically. These results might provide additional prognostic information compared to the conventional tumor histopathological factors.
Research perspectives
VEGFR1 has the potential to contribute to decision making regarding individual treatment in rectal cancer. A larger sample size and additional mRNA expression data are warranted to establish a superior prognosis model.
Furthermore, VEGFR1 expression and lymph node meta stasis affected the survival independently as well as synergistically. These results might provide additional prognostic information compared to the conventional tumor histopathological factors.
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Research background
Rectal cancer is one of the most common form of cancer in both men and women. Gene expression profiling for predicting the response and long-term prognosis of malignancies has been reported in recent decades. Vascular endothelial growth factor (VEGF) and class Ⅲ β-tubulin (TUBB3) have been reported to play a vital role in cancer progression. However, few studies focused on their role in rectal cancer.
Research motivation
We try to explore the potential prognostic value of VEGFR1 and TUBB3 for long-term survival in non-metastatic rectal cancer.
Research objectives
A total of 75 patients diagnosed with primary rectal adenocarcinoma without metastases were retrospectively analyzed.
Research methods
Multiplex branched DNA liquidchip technology was applied to detected mRNA expressions of VEGFR1 and TUBB3. The cutoff point of mRNA expression was determined by Cutoff Founder.
Research results
VEGFR1 expression was positively correlated to TUBB3. Patients with both low expression of TUBB3 and VEGFR1 presented a better overall survival (OS). In addition, VEGFR1 and lymph node metastasis had potential as prognostic factors for OS in non-metastatic rectal cancer patients, and the combination of WJGO|www.wjgnet.com 
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